RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Eureka Therapeutics, a Bay Area immunotherapy company, began a US Phase I/II clinical trial of its liver cancer T-Cell therapy at the City of Hope Hospital in Los Angeles. Last year, the candidate completed a small proof-of-concept trial among heavily pre-treated liver cancer patients in China that showed early signs of efficacy. ET140202 ARTEMIS™ includes a propriety antibody that attaches to a protein unique to liver cancer and also features a re-engineered T-Cell that greatly reduces the cytokine release syndrome that plagues most other T-Cell therapies. Source: China Biotoday
